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Introduction
Many variants in the NLRP3 gene are associated with a
particular spectrum of autoinflammatory diseases or her-
editary recurrent fevers (HRFs), including familial cold
autoinflammatory syndrome (FCAS), Muckle Wells Syn-
drome (MWS), and chronic infantile neurologic, cuta-
neous and articular syndrome (CINCA), also known
as neonatal onset multisystem inflammatory disease
(NOMID). These are now subsumed under the umbrella
term CAPS (cryopyrin-associated periodic syndromes).
However, CAPS is rarely encountered in any population
and is often difficult to identify. Extension of genetic
screening to a genomic scale may soon become routine,
but that development will require definition of the identi-
ties and ontology of the constellations of symptoms
involved, in order for bioinformatics applications to keep
pace. Patients with clinical features suggestive of these
conditions were analysed for NLRP3 variants.
Objectives
To explore the prevalence of NLRP3 variants in patients
with autoinflammatory disorders in order to establish a
consistent pattern of associated symptoms.
Methods
Genomic DNA from 91 unrelated patients referred for
genetic testing for any of the NLRP3-associated diseases
was screened for variants in exon 3 of NLRP3 by PCR
and automated DNA sequencing. Diverse symptoms
were recorded when possible and compared with the out-
come of genetic testing.
Results
Heterozygous missense substitutions in NLRP3 (NM_
001243133.1) were found in 16 of the 91 patients (17.6%),
including p.V198M, p.D303N, p.P315L, p.T348M, p.
V351M, p.T436I, p.G569R, and p.Y570F variants. In addi-
tion to the well-known CAPS signs of recurrent fever, urti-
carial rash and sensorineural hearing loss, symptoms
relatively frequently reported in NLRP3 variant-positive
patients included chronic meningitis or headache (9/14
with NLPR3 variant vs. 6/38 without) uveitis or iritis (8/15
vs. 10/41), growth retardation (6/14 vs. 5/37) epiphyseal or
patellar growth (5/14 vs. 1/35) and learning difficulties
(4/14 vs. 3/35). In addition, several patients with multiple
symptoms characteristic of CAPS were mutation-negative,
and at least 9 patients with or without a genetic diagnosis
developed AA amyloidosis.
Conclusion
In addition to the more typical symptoms, this study high-
lighted distinctive neurological characteristics of some
CAPS cases. These results indicate a large degree of
genetic and symptomatic heterogeneity in NLRP3-related
syndromes and suggest that other, as yet unidentified,
genes and other factors may be involved in producing a
CAPS-like phenotype. Such factors accrue to produce
symptomatic recurrent fever disease with an accompany-
ing heightened risk of developing AA amyloidosis. Autoin-
flammatory diseases continue to drive investigation of the
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